News

GlaxoSmithKline confronts new bribery allegations, this time in Iraq

Bribery allegations against GlaxoSmithKline are no longer confined to China. New claims have forced the pharma giant to open investigations on a second front, with the company now looking into possible corruption in Iraq, the company said Sunday.

Sanofi misled investors with rosy Lemtrada predictions, lawsuit alleges

Sanofi investors are fed up with disappointing news on the multiple sclerosis drug Lemtrada. Vaunted as a potential blockbuster, the drug hasn't even made it to market in the U.S. Now, some investment funds are suing the French drugmaker, saying executives talked up Lemtrada in public--and kept bad news from the FDA private.

Mallinckrodt bets $5.6B on Questcor and its controversial Acthar drug

Ireland's Mallinckrodt has been on a major growth spurt since its spinoff last spring from medical device maker Covidien--and it made another big move Monday in its bid to become a major specialty pharma company.

Sun Pharma hopes to turn fortunes of Ranbaxy around with $3.2B buyout

Sun Pharmaceutical has been shopping for deals that would give it more exposure to the U.S. market, and now it has pulled off a stunner. The Indian drugmaker will pay $3.2 million to buy competitor Ranbaxy Laboratories, a company with serious issues but one with big potential in the world's largest market.

Glaxo fires some China staff for malpractice amid stepped-up surveillance

With GlaxoSmithKline's China operations under investigation amid bribery allegations, the company is keeping its employees there under a more watchful eye.

Novartis fighting two-pronged legal battle in India on Galvus patent

Novartis, already in a legal battle to try to keep India's Wockhardt from launching a generic of its diabetes blockbuster Galvus, says it is now trying to prevent Biocon from doing the same thing.

British cost watchdog backtracks again on Roche's Tarceva

After intitially recommending Roche's targeted cancer drug Tarceva for use by Britain's National Health Service, the U.K.'s National Institute for Health and Care Excellence said in February it was reviewing the recommendation. Now, it looks likely to revert back to its original stance--a reversal of fortune the Swiss drugmaker is pleased with.

Amgen, GSK part on fast-selling Prolia, mostly

GlaxoSmithKline and Amgen are parting ways on Prolia, their comarketed osteoporosis med that's been among the fastest-growing products approved in the last few years. Amgen will take over the task in most areas under their agreement, leaving GSK freer to buckle down on some new launches of its own.

FDA's OK of opioid overdose treatment doesn't quell backlash over Zohydro

In the wake of the controversy over the FDA's decision to approve Zohydro, a pure hydrocodone drug that has no tamper-resistant technology tied to it, FDA Commissioner Margaret Hamburg Thursday used the approval of a new overdose treatment that anyone can carry to make her case that the FDA is just as concerned as everyone else about opioid drug abuse in the country.

Meda spurns Mylan takeover bid

Just four months after closing its $1.75 billion acquisition of Agila Specialities, generic drug maker Mylan is eyeing another takeover candidate--Sweden's Meda AB. Pennsylvania-based Mylan is talking with advisers about a takeover bid that could be made at a "significant premium" to Meda's $4.5 billion market value, according to sources quoted by the Financial Times.

Canadian drugmaker's Indian plant joins FDA import ban parade

The FDA has banned a handful of plants from some of India's biggest drugmakers in the last year, actions that have led to grumbling that the regulator is picking on Indian-owned operations. But now a plant in India owned by a Canadian firm has gotten the same treatment, an import alert that blocks products from being shipped to the U.S.

On a roll in Ireland, Alexion plots 200-job supply chain hub

Alexion, like many of its pharma peers, has moved some operations to Ireland to enjoy the country's low tax rate. Now, it's beefing up those operations.

Big Pharma dusts itself off in China scandal, but crackdown isn't over

Nine months after GlaxoSmithKline's bribery scandal first ignited a corruption hunt among Big Pharma companies in China, drugmakers--GSK excepted--are returning to the strong emerging-markets growth they're accustomed to in the country.

More scrutiny, less pay? U.K. docs collected less cash from pharma in 2013

Pharma's payments to doctors are diminishing on both sides of the Atlantic. A new report in Britain finds that drugmakers forked over £38.5 million ($63.9 million) to doctors last year. That's slightly less than the 2012 total of £40 million.

Novartis ousts top Japanese execs amid fresh misconduct allegations

Novartis has cracked down on its Japanese management. The Swiss drugmaker pushed out its top three executives Thursday, after a scathing report from a panel investigating misconduct in a leukemia drug trial.

Sanofi CEO vows to 'go beyond' handouts, hit double-digit growth in Africa

Just days after GlaxoSmithKline announced it would open a new R&D lab and invest more than $200 million in Africa, Sanofi CEO Chris Viehbacher is affirming his country's devotion to Africa, too.

Novartis Japan staffers shredded and deleted to cover trial misconduct, panel finds

Novartis' Japanese unit didn't fake clinical data in a head-to-head leukemia drug study, an investigatory panel found. But that doesn't mean the Swiss drugmaker's staff is off the hook in its latest Japanese scandal. According to the panel's report, employees not only broke the rules repeatedly--they also engaged in a cover-up.

GlaxoSmithKline yanks Paxil batches after FDA warning letter

GlaxoSmithKline has its second recall in as many weeks on its hands, this time affecting batches of the antidepressant Paxil that contain an ingredient manufactured at an Irish plant the FDA says isn't up to snuff.

Can Auxilium's ED hopeful Stendra score with provocative March Madness ads?

Auxilium is marketing Vivus' new erectile dysfunction pill Stendra with a jazzy, suggestive promo video during March Madness, when millions of men are glued to the games.

Amarin triples size of Vascepa sales force with Kowa promo deal

It hasn't been easy being Amarin over the last several months. The Irish drugmaker slammed into one obstacle after another. Read more from FiercePharmaMarketing>>